Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a cytosolic multiprotein complex that acts as a key sensor in the innate immune system (1.1.2, 1.4.2). It is composed of three primary components: the NLRP3 sensor protein, the apoptosis-associated speck-like protein containing a CARD (ASC) adaptor, and the pro-caspase-1 effector, with NIMA-related kinase 7 (NEK7) serving as an essential scaffolding protein for its activation (1.1.1, 1.2.2, 1.5.2). Activation of the NLRP3 inflammasome typically follows a two-step model involving a priming signal (e.g., via TLRs) and an activation signal (e.g., potassium efflux or mitochondrial stress) (1.3.1, 1.5.2). Once assembled, the complex activates caspase-1, which processes the precursors of interleukin-1 beta (IL-1β) and interleukin-18 (IL-18) into their active forms and triggers pyroptosis, a proinflammatory form of cell death (1.1.1, 1.4.1). Aberrant activation of this pathway is linked to numerous chronic inflammatory, metabolic, and neurodegenerative conditions, including gout, type 2 diabetes, and Alzheimer's disease (1.1.2, 1.5.3). Consequently, the NLRP3 inflammasome is a major therapeutic target, with various small molecules like MCC950 and biologics like canakinumab in development or use to inhibit its assembly or neutralize its downstream products (1.4.2, 1.5.1).
Direct inhibition of NLRP3 ATPase activity, prevention of NLRP3 oligomerization, inhibition of caspase-1 activation, neutralization of downstream cytokines (IL-1β, IL-18), and inhibition of the priming signal (NF-κB) (1.3.1, 1.4.1, 1.5.1).
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome (NLRP3 inflammasome).